Utynam's Heirs


A monthly column devoted to IP curiosities and controversies, named in honour of John of Utynam - who received the world's first recorded patent in 1449

diary@managingip.com

The drug that dare not speak its name

Utynam was pleased to receive a piece of news from a Chinese law firm about Pfizer's recent victory in a Beijing court over a patent related to its anti-impotence drug Viagra.

In an email accompanying a press release prepared by Peksung, which advised Pfizer in its long-running dispute with a group of Chinese companies over the patent, the sender informed Utynam that "a decision was made today by Beijing Higher Court regarding the Chinese patent on Pfizer's popular drug".

Utynam thought little more of Peksung's enigmatic refusal to name its client's blockbuster drug until he sent a reply thanking the firm for its timely update on developments in the Viagra case. The email bounced back having been rejected by the firm's electronic gatekeepers for containing a banned keyword.

Utynam is intrigued to know how Pfizer's in-house...


Please log in to read the rest of this article.

New to Managing Intellectual Property? Take advantage of one week’s FREE access and become a Managing IP member today. It’s free to join and the benefits start straight away.

Already registered?

Please make sure you log in to read the rest of the article.

Log in

Join us now

Gain 7 days FREE access when you register now.

Join here

More from the Managing IP blog


April 2014

India's trade mark office goes digital

India’s legal system, including its trade mark registry, has long been criticised for long pendency times and a morass of bureaucratic obstacles. However, a recent push toward digitisation has brought much-welcomed efficiency gains. Peter Leung reports



Most read articles

Supplements